Participant of ASX, Chi-X, Sydney Stock Exchange

ABN 95 092 989 083 | AFSL 247 100

Level 14 172 St Georges Terrace PERTH WA 6000 PO Box 7625 CLOISTERS SQUARE WA 6850

P: +61 8 9288 3388

Level 21 133 Castlereagh Street SYDNEY NSW 2000 PO Box R1931 **ROYAL EXCHANGE NSW 1225** P: +61 2 9024 9100


Neometals Ltd

2H 2017 lithium price surprising the market

On 5 July 2017, NMT and Mt Marion JV partner Mineral Resources (ASX:MIN) announced that pursuant to the terms of the Offtake Agreement with their partner, Ganfeng Lithium, the price payable for 6% spodumene concentrate increased from US\$750/t to US\$841/t (CFR, China), effective 1 July 2017.

State One Stockbroking comments

We note that Galaxy Resources (ASX:GXY) is getting up to US\$905/t (some US\$64/t higher) for 6% grade equivalent. Nevertheless, NMT's 12% price hike (for 6% spodumene concentrate produced at Mt Marion) indicates to us that the broader lithium market remains in robust health. Recent press and analyst reports suggest that the market is revising up near and medium-term Li price expectations - primarily on the back of revised Li-battery demand forecasts (for New Energy Vehicles (NEVs) in particular). We note that in late June, Macquarie Bank - after predicting last year an oversupply of the commodity upgraded their forecasts for the lithium price in 2020-2022 by 20-30% and lifted their outlook for several local lithium players. In a 3 July update, wellrespected lithium industry expert Joe Lowry (Global Lithium) forecasts that "moving into Q3, pricing in China is going up rather than down" and dismisses fears of DSO (direct shipped ore) from Australia negatively impacting supply or market prices. We believe that market concern over Li price direction is largely to blame for the broad-based sell-off seen in lithium stocks in the first half of the year. As these fears are allayed (even reversed), we suggest that lithium stock prices could rebound significantly.



Our SOTP valuation for NMT of A\$237m or A\$0.42ps, indicates some 40% upside potential. We believe that the Mt Marion Lithium Project has clearly demonstrated management's ability to identify opportunities, de-risk projects, and bring on board JV partners for final commercialisation. A cashrich and market-knowledgeable operator is looking to replicate this success in the downstream lithium-beneficiating space. Risks to our earnings profile and target price include, but are not limited to: the sale of NMT's remaining 13.8% interest in Mt Marion, lithium hydroxide/lithium carbonate and AUD:USD exchange rate volatility, project development at Barrambie Titanium (NMT 100% interest), and development of the group's downstream lithium Projects (various interests).

7 July 2017

Share Price: A\$0.295 (close 6 July 2017)

Target Price: A\$0.42

Recommendation Speculative Buy


Risk Assessment **Higher**

Resources - Lithium

David Brennan, CFA Senior Investment Analyst dbrennan@stateone.com.au +61 (0)2 9024 9142

Neometals Ltd ASX Code **NMT** 52 week range A\$0.25-A\$0.46 Market Cap (ASm) 156 Shares Outstanding (m) 546 Av Daily Turnover (shares) 0.93m **ASX All Ordinaries** 5.796 FY17E BV per share (A\$) 0.14 EPS FY17E (A\$) 0.0 Net Cash/(debt)) FY17E (A\$m) 63

Relative price performance (Source: IRESS)



Source: IRESS

Participant of ASX, Chi-X, Sydney Stock Exchange

Financial Statements

Neometals Limited

Year ending June

| Profit & Loss Statement (A\$M) | FY16A | FY17E | FY18E | FY19E | FY20E |
|--------------------------------------|--------|-------|-------|-------|-------|
| Revenue | 0.0 | 6.0 | 0.0 | 0.0 | 0.0 |
| Mining | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Processing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| NMT Corporate/Admin | (4.9) | (6.5) | (3.0) | (3.0) | (3.0) |
| EBITDA | (4.9) | (0.5) | (3.0) | (3.0) | (3.0) |
| Depreciation & Amortisation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating profit | (4.9) | (0.5) | (3.0) | (3.0) | (3.0) |
| NOI /income from 13.8% of Mt Marion | 88.3 | 0 | 135 | 0 | 0 |
| EBIT | 83.4 | (1) | 132 | (3) | (3) |
| Interest income | 0.7 | 2.9 | 2 | 5 | 5 |
| Interest expense | (0.3) | (0.0) | 0 | 0 | 0 |
| Tax expense | 0.8 | (0.2) | (13) | (1) | (0) |
| Reported NPAT | 84.6 | 2 | 121 | 1 | 1 |
| Normalised NPAT | (3.7) | 2 | 121 | 1 | 1 |
| EBITDA Margin (%) | na | na | na | na | na |
| Operating profit margin (%) | na | na | na | na | na |
| EPS Reported (A\$) | 0.15 | 0.00 | 0.22 | 0.00 | 0.00 |
| EPS Normalised (A\$) | (0.01) | 0.00 | 0.22 | 0.00 | 0.00 |
| EPS grow th (%) | nm | nm | nm | -99% | -18% |
| DPS - Declared (A\$) | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Avg. no. of fully-diluted shares (m) | 542 | 565 | 558 | 550 | 550 |
| YE no. of fuly-diluted shares (m) | 565 | 565 | 550 | 550 | 550 |
| | | | | | |

| Cash Flow Statement (A\$M) | FY16A | FY17E | FY18E | FY19E | FY20E |
|---------------------------------------|--------|-------|-------|-------|-------|
| EBITDA | (4.5) | (1) | (3) | (3) | (3) |
| Investment in working capital | (1.1) | 1 | 0 | 0 | 0 |
| Tax expense | 0.8 | (0) | (13) | (1) | (0) |
| Operating Cash Flow | (4.7) | (0) | (16) | (4) | (3) |
| Capex | (1.3) | (2) | (2) | (2) | (2) |
| Other investments | 0.0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.3) | (2) | (2) | (2) | (2) |
| Net interest received / (paid) | 0.4 | 3 | 2 | 5 | 5 |
| Debt draw dow n / (repayment) | (1.9) | (0) | 0 | 0 | 0 |
| Dividends paid | (11.2) | (11) | (11) | (11) | (11) |
| Equity raised / (repaid) / Other Adj. | 2.5 | 0 | (5) | 0 | 0 |
| Financing Cash Flow | (10.1) | (8) | (14) | (6) | (6) |
| Non-operating & Other | 88.0 | 1 | 135 | 0 | 0 |
| Inc/(Dec) in Cash | 71.8 | (10) | 102 | (12) | (12) |

| Balance Sheet (A\$M) | FY16A | FY17E | FY18E | FY19E | FY20E |
|----------------------------------------|-------|-------|-------|-------|-------|
| Cash & Equivalents | 73.2 | 63 | 166 | 154 | 142 |
| Receivables | 0.6 | 0 | 0 | 0 | 0 |
| Inventories | 0.0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.6 | 0 | 0 | 0 | 0 |
| PPE and Exploration & Development | 12.0 | 14 | 16 | 18 | 20 |
| Deferred tax asset | 0.0 | 0 | 0 | 0 | 0 |
| Other Non Current Assets | 8.3 | 8 | 8 | 8 | 8 |
| Total Assets | 95.7 | 86 | 190 | 180 | 171 |
| Payables and other current Liabilities | 1.6 | 0 | 0 | 0 | 0 |
| Short Term Debt | 0.0 | 0 | 0 | 0 | 0 |
| Long Term Debt | 0.0 | 0 | 0 | 0 | 0 |
| Other Non Current Liabilities | 4.4 | 5 | 5 | 5 | 5 |
| Total Liabilities | 6.1 | 5 | 5 | 5 | 5 |
| Total Equity | 89.6 | 81 | 185 | 175 | 166 |
| Net Cash/(debt) | 73 | 63 | 166 | 154 | 142 |

| Top 3 Shareholders | % | Date |
|-------------------------------------|------|--------|
| David Reed | 11.7 | |
| Melaid Holding Inc | 6.8 | Sep-16 |
| HSBC Custody Nominees (Australia) I | 3.7 | |

Source: Company, IRESS, State One Stockbroking forecasts

| Received Lithium Price | FY16A | FY17E | FY18E | FY19E | FY20E |
|------------------------------------------------------------------|-------|--------|--------|--------|--------|
| Spodumene (6% Li ₂ O) (US\$/t, CIF) | | 525 | 525 | 536 | 546 |
| AUD:USD | | 0.75 | 0.75 | 0.75 | 0.75 |
| Spodumene (Li ₂ 0)(A\$/t, CIF) | | 700 | 700 | 714 | 728 |
| Lithium Hydroxide and Lithium Carbonate basket price (US\$/t) | | 15,000 | 12,500 | 10,000 | 10,200 |

| Production (Mt Marion) | FY16A | FY17E | FY18E | FY19E | FY20E |
|-------------------------------|-------|-------|-------|-------|-------|
| Spodumene tonnage (kt) (100%) | 0 | 90 | n/a | n/a | n/a |

We assume NMT completes the planned sale of its remaining 13.8% in Mt Marion by end-June 2017. From FY18E, we assume zero tonnage attributable to NMT from Mt Marion.

| Production (Downstream) | FY16A | FY17E | FY18E | FY19E | FY20E |
|-------------------------------|-------|-------|-------|-------|-------|
| Lithium Hydroxide and Lithium | 0 | 0 | 0 | 0 | 0 |
| Carbonate - combined tonnage | Ü | 0 | U | U | U |

We assume first production of Lithium Hydroxide (LiOH.H20) and Lithium Carbonate (Li2CO3) from NMT's proposed Malaysia-based downstream operation in FY21E (i.e., from mid-2020)

| Costs (A\$/t Spodumene conc.) | FY16A | FY17E | FY18E | FY19E | FY20E |
|-------------------------------|-------|-------|-------|-------|-------|
| Mining | na | na | na | na | na |
| Processing | na | na | na | na | na |
| Admin/Royalty/Other | na | na | na | na | na |
| Total unit cash costs | na | na | na | na | na |

| Resources (JORC) | Status | Mt | Grade (%) | Tonnes |
|-----------------------------------------------------|--------------------------------|------|-----------|------------|
| Mt Marion Lithium Project (Resource at Dec 2016) | Indicated | 28.9 | 1.35% | 390,150 |
| | Inferred | 48.9 | 1.4% | 674,820 |
| | Total | 77.8 | 1.37% | 1,064,970 |
| Barrambie Ti-V Project | TiO ₂ | 47.2 | 22.2% | 10,468,960 |
| | V_2O_5 | 47.2 | 0.63% | 297,360 |
| | Fe ₂ O ₃ | 47.2 | 46.7% | 22,042,400 |

Note: We assume NMT has zero interest in Mt Marion Resource as from end June 2017

| Leverage | FY16A | FY17E | FY18E | FY19E | FY20E |
|--------------------|-------|-------|-------|-------|-------|
| Net Debt/Equity | 82% | 79% | 90% | 88% | 86% |
| Gearing (ND/ND+E) | 76% | 74% | 87% | 85% | 83% |
| Interest Cover (x) | na | na | na | na | na |

| Valuation Ratios (x) | FY16A | FY17E | FY18E | FY19E | FY20E |
|----------------------------|-------|-------|-------|-------|-------|
| Normalised P/E | na | na | na | na | na |
| Price/OP Cash Flow | na | na | na | na | na |
| Book value per share (A\$) | 0.16 | 0.14 | 0.34 | 0.32 | 0.30 |
| EV/EBITDA | na | na | na | na | na |
| ROE (%) | na | na | na | na | na |


| SOTP Valuation | (A\$m) | (A\$/share) | Comment |
|---------------------------------------|--------|-------------|-----------------------|
| Mt Marion sales proceeds (risked) | 101 | 0.18 | Asking price less 20% |
| ELi Project - Malaysia (unrisked) | 356 | 0.63 | State One estimate |
| Risk discount | 90% | | |
| ELi Project - Malaysia (risked) | 36 | 0.06 | 10% of unrisked NPV |
| ELi Processing - technology licensing | 2 | 0.00 | Nominal |
| Conventional Lithium Processing | 2 | 0.00 | Nominal |
| Battery recycling | 5 | 0.01 | Nominal |
| Barrambie Titanium & Neomet tech. | 15 | 0.03 | Nominal |
| Equity interest in Hannans (HNR) | 13 | 0.04 | <u></u> |
| Group Enterprise value | 173 | 0.31 | |
| Net (debt)/cash (FY17E) | 63 | 0.11 | _ |
| Group Equity value | 237 | 0.42 | |

We assume NMT will <u>dispose of its remaining 13.8% interest in the Mt Marion Lithium Project in FY18E,</u> to concentrate on its downstream Li-processing projects, and in progressing the Barrambie Titanium Project.

Participant of ASX, Chi-X, Sydney Stock Exchange

Figure 1: Sum-of-the-parts (SOTP) valuation

| | (A\$m) | (A\$ps) | Comment |
|-----------------------------------------------|--------|---------|-------------------------------------------|
| Mt Marion Lithium (13.8% interest) (risked) | 126 | 0.22 | US\$96m @ US\$0.75 |
| Risk weighting | 20% | | 20% discount for transaction risk/timing |
| Mt Marion Lithium (13.8% interest) (unrisked) | 101 | 0.18 | i.e., 80% of asking asking price |
| ELi Processing -Malaysia (unrisked) | 356 | 0.63 | State One NPV estimate |
| Risk weighting | 90% | | 90% discount |
| ELi Processing - Malaysia (risked) | 36 | 0.06 | i.e., 10% of State One unrisked valuation |
| ELi Processing - technology licensing | 2 | 0.00 | Nominal |
| Conventional Lithium Processing | 2 | 0.00 | Nominal |
| Battery recycling | 5 | 0.01 | Nominal |
| Barrambie Titanium & Neomet tech. | 15 | 0.03 | Nominal (versus PFS NPV of A\$355m) |
| Equity interest in Hannans (ASX:HNR) | 13 | 0.02 | 709m shares @ A\$1.8cps |
| Group Enterprise value | 173 | 0.31 | - |
| Net cash/(debt) (FY17E) | 63 | 0.11 | State One estimate |
| Group Equity value | 237 | 0.42 | |



Source: IRESS, Company, State One Stockbroking forecasts

General Advice Warning

The contents of this document have been prepared without taking account of your objectives, financial situation or needs. You should, before taking any action to acquire or deal in, or follow a recommendation (if any) in respect of any of the financial products or information mentioned in this document, consult your own investment advisor to consider whether that is appropriate having regard to your own objectives, financial situation and needs. Whilst State One Stockbroking Ltd believes information contained in this document is based on information which is believed to be reliable, its accuracy and completeness are not guaranteed and no warranty of accuracy or reliability is given or implied and no responsibility for any loss or damage arising in any way for any representation, act or omission is accepted by State One Stockbroking Ltd or any officer, agent or employee of State One Stockbroking Ltd. If applicable, you should obtain the Product Disclosure Statement relating to the relevant financial product mentioned in this document (which contains full details of the terms and conditions of the financial product) and consider it before making any decision about whether to acquire the financial product.

Disclosure

This report was prepared solely by State One Stockbroking. ASX did not prepare any part of the report and has not contributed in any way to its content. The role of ASX in relation to the preparation of the research reports is limited to funding their preparation by State One Stockbroking, in accordance with the ASX Equity Research Scheme. ASX does not provide financial product advice. The views expressed in this research report may not necessarily reflect the views of ASX. To the maximum extent permitted by law, no representation, warranty or undertaking, express or implied, is made and no responsibility or liability is accepted by ASX as to the adequacy, accuracy, completeness or reasonableness of the research reports.

The directors and associated persons of State One Stockbroking Ltd may have an interest in the financial products discussed in this document and they may earn brokerage, commissions, fees and advantages, pecuniary or otherwise, in connection with the making of a recommendation or dealing by a client in such financial products. State One Stockbroking Ltd has also received a commission on the preparation of this research note. The Research Analyst who prepared this report hereby certifies that the views expressed in this research document accurately reflect the analyst's personal views about the company and its financial products. The research analyst has not been and will not be receiving direct or indirect compensation for expressing the specific recommendations or views in this report. This research at all times remains the property of State One Stockbroking Ltd. And as such cannot be reprinted, distributed, copied, posted on the internet, in part or whole, without written prior approval from the Executive Director of State One Stockbroking Ltd.

Alan Hill Executive Chairman Phone: +61 8 9288 3388 ahill@stateone.com.au

Morris Levitzke Equities Advisor Phone: +61 8 9288 3315 mlevitzke@stateone.com.au

Alexander Bax Equities Advisor Phone +61 8 9288 3340 abax@stateone.com.au Ric Heydon Equities & Derivatives Advisor Phone: +61 8 9288 3307 rheydon@stateone.com.au

Graeme Johnson
Equities & Derivatives Advisor
Phone: +61 8 9288 3316
gjohnson@stateone.com.au

David Zhang Equities Advisor Phone: +61 2 9024 9130 dzhang@stateone.com.au Mark Sullivan Institutional Dealer Phone: +61 2 9024 9134 msullivan@stateone.com.au

Yitz Barber Equities Advisor Phone: +61 2 9024 9107 ybarber@stateone.com.au

David Brennan Senior Investment Analyst Phone: +61 2 9024 9142 <u>dbrennan@stateone.com.au</u> Thomas Tan Equities Advisor Phone: +61 2 9024 9131 ttan@stateone.com.au

Tammie Wong Equities Advisor Phone: +61 2 9024 9133 twong@stateone.com.au